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Microarray analysis reaches increasing popularity during the investigation of prognostic gene clusters in oncology. The
standardisation of technical procedures will be essential to compare various datasets produced by diﬀerent research groups. In
several projects the amount of available tissue is limited. In such cases the preamplification of RNA might be necessary prior to
microarray hybridisation. To evaluate the comparability of microarray results generated either by amplified or non amplified
RNA we isolated RNA from colorectal cancer samples (stage UICC IV) following tumour tissue enrichment by macroscopic
manual dissection (CMD). One part of the RNA was directly labelled and hybridised to GeneChips (HG-U133A, Aﬀymetrix),
the other part of the RNA was amplified according to the “Eberwine” protocol and was then hybridised to the microarrays.
During unsupervised hierarchical clustering the samples were divided in groups regarding the RNA pre-treatment and 5.726
diﬀerentially expressed genes were identified. Using independent microarray data of 31 amplified vs. 24 non amplified RNA
samples from colon carcinomas (stage UICC III) in a set of 50 predictive genes we validated the amplification bias. In conclusion
microarray data resulting from diﬀerent pre-processing regarding RNA pre-amplification can not be compared within one
analysis.
Copyright © 2009 Roland S. Croner et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Microarray-based investigations of genome wide gene
expression have become a popular method for the molecular
characterisation of various tissue types. In molecular oncol-
ogy prognosis-related genes could be identified concerning
various cancer types [1–5]. Especially in colorectal carci-
noma gene clusters related to metastasis, tumour recurrence
or chemoradiation were described [4, 6–8]. Microarray
analysis in most of these studies was not dependent on RNA
amplification, as enough RNA could be isolated from the
tumours. Whenever tissue is limited and a high-throughput
analysis is in concern, amplification of RNA by in vitro
transcription is essential. However, using amplification, one
has to be sure that the RNA is amplified linear, meaning
that gene expressions will be comparable between native and
amplified RNA. This is necessary, as more and more data
are generated with diﬀerent methods, stored at the internet
being available for the research community. Recently the
limited comparability of gene expression profiles between
studies using diﬀerent techniques has been demonstrated
[5]. However, there is an ongoing discussion if microarray
data of non amplified and amplified RNA samples are
comparable. The aim of our study was to evaluate to which
extend (1) the microarray data based on amplified RNA are
reproducible, (2) the expression data from amplified and
native RNA are comparable, and (3) if tumour specific genes
are aﬀected by an amplification bias.
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2. Material and Methods
2.1. Patients and Experimental Procedure. Primary tumours
of four patients with colorectal carcinomas stage UICC IV
resected at the Department of Surgery at the Friedrich-
Alexander-University Erlangen-Nuremberg were chosen for
the analysis. No patient received neoadjuvant treatment
prior to surgery. By approval of the Ethical Committee
of our University and by patient consent, conformity to
the ethical guidelines for human research respecting the
principles of the Declaration of Helsinki was provided. After
tumour enrichment by cryotomy after manual dissection
(CMD) RNA was isolated from each sample [9]. One
part of the RNA of each sample was hybridized to the
microarray without amplification; the other part underwent
amplification prior to microarray hybridization (Figure 1).
For validation purpose the microarray data of amplified
RNA from 31 colon carcinoma samples stage UICC III
versus the microarray data of not amplified RNA from 24
colon carcinoma samples were used. Patient selection, tissue
workup, and amplification protocol were equally in each
group.
2.2. Sample Workup and RNA Isolation. The tissue was
inserted into a cryotube (Roth, Karlsruhe, Germany)
together with Tissue-Tek (Zakura, Zoeterwoude, Nether-
lands) and immediately shock frozen in liquid nitrogen after
surgery and stored at −80◦C until further workup. CMD
was performed as recently described [9]. RNA isolation was
performed in the same way from all four tissue samples using
commercial kits (RNeasy-Kit, Qiagen, Hilden, Germany),
following the manufacturers’ protocol. Each sample was
added to the Qiagen spin column, and centrifuged to bind
the RNA to the matrix. The column was washed with the
buﬀers provided in the kit, and the RNA was finally eluted
with distilled H20. Within this procedure a DNAse (Qiagen,
Hilden, Germany) digestion was included following the
manufacturers’ suggestion. RNA quality and quantity was
determined by the “Lab on a Chip” method (Bioanalyzer
2100, Agilent Technologies, Palo Alto, USA) following the
manufacturers’ instructions [10]. A total of 50 ng to 100 ng
of each RNA sample was loaded/well. The analyser allows for
visual examination of both the 18S and 28S rRNA bands as
measure of RNA integrity.
The 3′/5′-ratios for the housekeeping genes glycerin-
aldehyde-3-phosphatase (GAPDH) and ß-actin supplied by
the GeneChip were used as further parameters for RNA
quality and to exclude partial degradation. A 3′/5′-ratio
below the value of 3 was regarded as an indicator for
good RNA quality according to the manufacturers’ protocol
(Aﬀymetrix, Santa Clara, USA) [11].
2.3. RNA Amplification. Amplification of RNA was per-
formed with the Message Amp aRNA kit (Ambion, Austin
(Tx), USA) according to the manufacturers’ instructions,
using 200 ng of total RNA for each sample. Briefly, first
strand cDNA syntheses were primed with the T/Oligo (dT)
primer to synthesize cDNA with a T/promoter sequence
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Figure 1: Experimental procedure. RNAwas isolated from tumours
after CMD; one part of the RNA underwent amplification and the
other part was hybridized without preamplification to microarrays.
from the poly (A) tails of massages by reverse transcription.
The second strand cDNA synthesis converted cDNA with the
T7 promoter primer into double-stranded DNA (dsDNA)
template for transcription. Following a cDNA purification
step an in vitro transcription was done, generating multiple
copies of aRNA from the double-stranded cDNA templates.
Finally, in another purification step, unincorporated NTPs,
salts, enzymes, and inorganic phosphate were removed. In
a second round, the additional amplification of the RNA
sample was achieved. Besides using diﬀerent primers for
the second round, the same reagents and methodology were
used. During this second round the biotin labelling of the
probe took place before the in vitro transcription step.
Hereunto, for each sample, 3.75 µL of 10mM biotin 11-CTP
and 3.75 µL of 10mM biotin-16-UTP were added and the
probe dried in a vacuum centrifuge concentrator.
2.4. Labelling of “Native” RNA and GeneChip Hybridization.
Biotin-labelled cRNA was generated by in vitro
transcription as described previously and hybridized
to the GeneChips (HG-U133A, Aﬀymetrix) following
the manufacturers’ instructions. For first-strand cDNA
synthesis, 9 µL (13.5 µg) of total RNA were mixed
with 1 µL of a mixture of three polyadenylated control
RNAs, 1 µL 100 µM T7-oligo-d(T)21-V primer (5′-
GCATTAGCGGCCGCGAAATTAATACGACTCACTATA-
GGGAGA(T)21V-3′), incubated at 70◦C for 10min and
put on ice. Next, 4 µL of 5x first strand buﬀer, 2 µL 0.1M
DTT and 1 µL 10mM dNTPs were added and the reaction
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Table 1: Pearson correlations of microarray signals and detection
P-values between non amplified (NA) and amplified (PA) RNA
samples from four colorectal carcinoma specimens. The RNA was
isolated from identical samples and underwent either amplification
or no amplification prior to microarray hybridization.
Samples Signals Detection P-value
1 NA versus 1 PA 0.91 .81
2 NA versus 2 PA 0.89 .75
3 NA versus 3 PA 0.86 .79
4 NA versus 4 PA 0.91 .81
was preincubated at 42◦C for 2min. Then 2 µL (200U)
Superscript II (Life Technologies, Karlsruhe, Germany) were
added and incubation continued at 42◦C for 1 hour. For
second strand synthesis, 30 µL of 5x second strand buﬀer,
91 µL of RNAse-free water, 3mL 10mM dNTPs, 4 µL (40 U)
E. coli DNA polymerase I (Life Technologies), 1 µL (12U)
E. coli ligase (TaKaRa Biomedical Europe, Gennevilliers,
France), 1 µL (2U) RNAse H (TaKaRa) were added and the
reaction was incubated at 16◦C for 2 hours. Then, 2.5mL
(10U) T4 DNA polymerase I (TaKaRa) were added at
16◦C for 5min. The reaction was stopped by adding 10 µL
0.5M EDTA, the double-stranded cDNA was extracted with
phenol/chloroform and the aqueous phase was recovered by
phase lock gel separation (Eppendorf, Hamburg, Germany).
After precipitation, the cDNA was restored in 12 µL of
RNAse-free water. Five microliters of ds cDNA were used
to synthesize biotinylated cRNA using the BioArray High
Yield Transcript Labeling Kit (Enzo Diagnostics, NY, USA).
Labelled cRNA was purified using the RNeasy mini kit
(Qiagen, Hilden, Germany). Fragmentation of cRNA,
hybridization to GeneChips, washing and staining as well as
scanning of the arrays in the Gene Array scanner (Agilent)
were performed as recommended by the Aﬀymetrix Gene
Expression Analysis Technical Manual. Signal intensities
and detection calls for statistical analysis and hierarchical
clustering were determined using the GeneChip 5.0
software.
2.5. Statistics. Significance levels of microarray results
between non amplified (NA) and amplified (PA) RNA
samples were calculated using the Mann-Whitney U-test
(P < .05, means diﬀerecially expressed). The average signal
intensity of PA/NAwas calculated as fold change (FC). Unsu-
pervised and supervised hierarchical cluster analyses of all
22.215 probe sets (HG-U 133A, Aﬀymetrix) were performed
(Spotfire, Decision Site, Somerville, USA). Diﬀerences in
signal intensity of microarray results between NA versus PA
were analysed regarding sequence length and chromosomal
localization. Pearson correlation of signals and detection P-
values from microarray results between NA versus PA were
investigated.
Moreover, validation of amplification bias was done for
22.215 gene expression values (HG-U133A, Aﬀymetrix) for
31 amplified RNA samples of colon carcinoma samples
versus 24 not amplified RNA samples of colon carcinoma
samples, all stage UICC III. The Pearson correlation was
calculated and the mean expression values and standard
deviation (log2) of 50 predictive genes for lymphatic metas-
tasis recently described have been compared [12]. For
validation purpose gene expressionmeasures were computed
with the RobustMultichip Average (RMA)method described
in Irizarry et al. [12] and implemented in the R-function
just RMA of the Bioconductor R package aﬀy. The statistical
analysis was performed with the open-source software R,
Version 2.6.1.
3. Results
3.1. Comparability of Amplified and Non Amplified RNA. In
the amplified test set 200 ng of RNA was used as the starting
yield. Two rounds of amplification of RNA resulted in
suﬃcient amounts of cRNAwith good quality for microarray
hybridization. The correlation of the microarray signals
between non amplified and amplified RNA reached 86%–
91%. The detection P-values of the microarray data corre-
lated in 75%–81% (Table 1). An unsupervised hierarchical
cluster analysis including all 22.283 probe sets from the
GeneChips separated all unamplified from the preamplified
RNA samples (Figure 2). All samples were correctly classified
regarding the method of RNA pretreatment. In the statistical
analysis (Mann-Whitney U-test, P < .05) 5.725 significantly
diﬀerentially expressed genes between non amplified and
amplified RNA samples could be identified. In 1.182 probe
sets of the microarray a significantly elevated signal intensity
of amplified versus non amplified samples could be detected.
In 4.543 probe sets significantly lower signal intensity
between amplified versus non amplified RNA could be
detected. The fold change (PA/NA) of the mean signals was
between 8 (bicaudal-D (BICD) mRNA) and 13 (myosin I× b
(MYO9b) mRNA). Several ribosomal RNA (e.g., 18S rRNA
gene) which were included on the microarrays as internal
control could be detected with a fold change of 273 between
amplified vs. non amplified samples. In 36% RNA with
increased FC and in 32% RNA with a decreased FC had a
sequence length between 1000–19000 bp. In 5% RNA with
increased FC and in 1% RNA with a decreased FC had a
sequence length >300000 bp (Figure 3(a)). Thirteen per cent
of genes with an increased FC were located on chromosome
1; 10% on chromosome 17; 9% on chromosome 6, and 8%
on chromosome 2. Eleven per cent of genes with decreased
FC were located on chromosome 19; 9% were located on
chromosome 2, chromosome 7, and chromosome 12, and
8% on chromosome 16 (Figure 3(b)).
3.2. Influence of RNA Amplification on Colorectal Cancer
Specific Genes. Various genes which have been recently
described participating in carcinogenesis and tumour pro-
gression in colorectal carcinomas could be identified with
significantly diﬀerent signals between amplified and non
amplified RNA samples (e.g., WNT3, APC, and VEGF).
VEGFB had a decreased FC of −5 and the APC gene −4.
Several genes involved in the cell cycle (CDC5, CDC6,
CDC2, CDC25C, CDC25A) were found with significantly
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Figure 2: Unsupervised (a) and supervised (b) hierarchical cluster analysis of microarray results from non amplified and amplified RNA
samples from colorectal carcinoma samples.
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Figure 3: Diﬀerences in total gene expressions between non amplified (NA) versus amplified (PA) RNA, regarding (a) sequence length of
genes and (b) chromosomal localization.
diﬀerent microarray signals with an FC between 3 and −4.
Matrix metalloproteinases as MMP-11, MMP14, and MMP
15 showed decreased FC between −4 and −9 (Table 2).
3.3. Validation of Amplification Bias. The Spearman correla-
tion of 22.115 probe sets (Aﬀymetrix HG-U133A) between
31 amplified RNA samples versus 24 not amplified RNA sam-
ples of colon carcinomas stage UICC III was 0.8 (Figure 4).
Comparing the mean microarray signals of 50 recently
described genes predictive for lymphatic metastasis only in
one case an equal value could be detected (210701 at). The
standard deviation in this case was less high without RNA
amplification. In most other genes substantially diﬀerences
were identified (Table 3).
4. Discussion
Gene expression profiling has become an attractive tool
for tissue typing and prognostic evaluations in cancer
research. For colorectal carcinoma several gene profiles
dividing healthy mucosa from tumours and for prognostic
classification could be identified [5, 7, 12–15]. Nevertheless
there is only a limited overlap in the described gene profiles
in most of these studies [5]. One reason for this finding
might be the fact that there is a brought variability of applied
techniques used during the analysis. Regarding the methods
of tissue handling and isolation, RNA preparation, and
microarray hybridization, various distributive factors may
influence the results. Especially, when only small amounts
of tissue can be harvested or only limited amounts of tissue
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Table 2: Diﬀerent gene expression values of cancer specific genes between non amplified (NA) and amplified (PA) RNA samples from
colorectal carcinoma samples.
Aﬀy Gb Bases Anotation Avg. Signals NA Avg. Signals PA FC PA/NA P
221455 s at NM 030753 56038
Wingless-type
MMTV integration
site family, member 3
(WNT3).
20 78 4 .04
212447 at AF161402 23,589 HSPC284 mRNA,
partial cds.
2480 9611 4 .01
201111 at NM 001253 50,649
Brain cellular
apoptosis
susceptibility protein
(CSE1).
2568 7431 3 .01
209056 s at NM 001253 62,329
CDC5 (cell division
cycle 5, S. pombe,
homolog)-like
(CDC5L).
1399 3861 3 .01
206458 s at NM 024494 54,746
Wingless-type
MMTV integration
site family, member
2B (WNT2B).
72 177 2 .01
207149 at L33477 1,102,757 Br-cadherin mRNA,
complete cds.
35 84 2 .04
204731 at NM 003243 225,660
Transforming growth
factor, beta receptor
III (TGFBR3).
602 1336 2 .04
219226 at NM 016507 73,062 CDC2-related protein
kinase 7 (CrkRS).
555 1131 2 .01
217366 at Z37994 3620 Alpha E-catenin
pseudogene.
30 6 2 .04
208504 x at NM 018931 3321 Protocadherin beta 11
(PCDHB11).
33 11 2 .04
201069 at NM 004530 27,516
Matrix
metalloproteinase 2
(MMP2).
1528 887 −2 .04
203968 s at NM 001254 15,268 Cell division cycle 6
(CDC6).
624 338 −2 .01
203918 at NM 002587 25,296 Protocadherin 1
(PCDH1).
544 290 −2 .04
208756 at U36764 9235 TGF-beta receptor
interacting protein 1.
4451 2355 −2 .01
210838 s at L17075 15,944 TGF-b superfamily
receptor type I.
277 127 −2 .01
206943 at NM 004612 49,063
Transforming growth
factor, beta receptor I
(TGFBR1).
331 150 −2 .01
212143 s at BF340228 9028
Insulin-like growth
factor binding protein
3.
1192 462 −3 .01
202039 at NM 004740 2089
TGFB1-induced
antiapoptotic factor 1
(TIAF1).
1000 371 −3 .01
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Table 2: Continued.
Aﬀy Gb Bases Anotation Avg. Signals NA Avg. Signals PA FC PA/NA P
203214 x at NM 001786 18927
Cell division cycle 2,
G1 to S and G2 to M
(CDC2).
3181 1174 −3 .01
160020 at Z48481 11,011
Membrane-type
matrix
metalloproteinase 1
(MMP1).
1258 437 −3 .01
217010 s at AF277724 46,558
Cell division cycle
25C splice variant 3
(CDC25C).
211 61 −3 .01
204696 s at NM 001789 31,134 Cell division cycle
25A (CDC25A).
123 34 −4 .01
203527 s at NM 000038 108,353 Adenomatosis
polyposis coli (APC).
85 23 −4 .01
210287 s at U01134 192,877
Soluble vascular
endothelial cell
growth factor
receptor (sflt).
143 37 −4 .01
203878 s at NM 005940 11,468
Matrix
metalloproteinase 11
(stromelysin 3)
(MMP11).
1546 400 −4 .01
203365 s at NM 002428 21,524
Matrix
metalloproteinase 15
(membrane-inserted)
(MMP15).
388 93 −4 .04
203683 s at NM 003377 3994
Vascular endothelial
growth factor B
(VEGFB).
422 78 −5 .01
217279 x at X83535 11,011
Membrane-type
matrix
Metalloproteinase
(MMP14).
244 27 −9 .01
204380 s at M58051 15,565
Fibroblast growth
factor receptor
(FGFR3).
224 25 −9 .01
207334 s at NM 003242 87,641
Transforming growth
factor, beta receptor II
(TGFBR2).
323 15 −16 .01
are available, the yield of RNA might not be suﬃcient
for microarray hybridization. Preprocessing of the RNA by
amplification becomes indispensable. Whether samples of
amplified RNA can be compared to samples with non ampli-
fied RNA is still discussed controversially. For the amplified
probes, we used the linear amplification technique which is
based on a double-stranded cDNA synthesis with an oligo-
dT primer coupled to the T7 RNA polymerase promoter
followed by an in vitro transcription into aRNA by T7 RNA
polymerase [16]. This is an established technique used for
RNA amplification procedures during microarray experi-
ments [17–19]. During two rounds of amplification enough
RNA in suﬃcient quality could be generated for microarray
hybridization which supports the reliability of the method.
The Aﬀymetrix (Santa Clara, USA) GeneChip technology
provides standardized protocols for microarray procedures
on a commercial platform which is frequently used in gene
expression profiling regarding colorectal tumours [4, 14,
20–24]. Using unsupervised hierarchical cluster analysis of
our microarray results we observed a separation of two
groups respecting the RNA pretreatment. We identified
5.725 significantly diﬀerentially expressed genes between non
amplified and amplified RNA samples. As amplified and non
amplified RNA referred to the same samples no separation
in clusters should have been occurred. The cluster results
and the identification of significantly diﬀerent expressed
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Table 3: Comparison of mean signals and standard deviation (sdv) of genes which were recently described as predictive for lymphatic
metastasis in colorectal carcinomas [12], between 31 amplified RNA samples of colon carcinomas and 24 RNA samples of colon carcinomas
not amplified prior to microarray hybridization.
Group Colon carcinoma Colon carcinoma
Samples; n 31 24
Stage UICC III III
Amplified yes no
ProbeSet ID gb Gene Bases
fold change log2
mean amplified
versus non
amplified
log2 mean log2 sdev log2 mean log2 sdev
205433 at NM 000055 BCHE 64562 1.05 4.36 0.71 4.16 0.21
211044 at BC006333 TRIM14 49,926 0.8 3.37 0.18 4.22 0.24
37547 at U85995 PTHB1 476,529 1.32 5.63 0.61 4.25 0.17
215973 at AF036973 HCG4P6 1060 0.89 4.07 0.36 4.56 0.21
214376 at AI263044 EST 363 0.99 4.53 0.36 4.55 0.14
216489 at AB046836 TRPM3 911,872 0.75 3.46 0.16 4.62 0.2
211201 at M95489 FSHR 192,237 0.76 3.55 0.21 4.65 0.16
214068 at AF070610 BEAN 56,130 0.74 3.45 0.41 4.66 0.21
216063 at N55205 HBBP1 1742 0.79 3.75 0.21 4.72 0.24
219791 s at NM 024748 FLJ11539 11,373 0.77 3.67 0.43 4.77 0.2
209353 s at BC001205 SIN3B 50,947 0.92 4.37 0.23 4.77 0.29
211381 x at AF168617 SPAG11 15,917 0.76 3.63 0.22 4.78 0.35
207021 at NM 007009 ZPBP 155,788 0.74 3.57 0.2 4.85 0.17
220227 at NM 024883 CDH4 684,743 0.74 3.77 0.19 5.12 0.38
210701 at D85939 CFDP1 139,780 1 5.12 0.42 5.12 0.22
220156 at NM 024593 EFCAB1 11,825 0.76 4.04 0.17 5.32 0.28
209883 at AF288389 GLT25D2 101,898 0.89 4.67 0.77 5.25 0.19
207031 at NM 001189 BAPX1 3661 1.04 5.54 0.67 5.32 0.29
206885 x at NM 022559 GH1 1636 0.76 4.14 0.27 5.47 0.25
212963 at BF968960 TM2D1 44,379 0.83 4.6 0.41 5.55 0.27
207897 at NM 001883 CRHR2 46,857 0.81 4.59 0.16 5.67 0.32
222083 at AW024233 GLYAT 23,218 0.64 3.69 0.21 5.72 0.37
214149 s at AI252582 ATP6V0E 51,138 0.86 5.07 0.49 5.87 0.58
220332 at NM 006580 CLDN16 22,493 0.82 4.71 0.25 5.75 0.21
220944 at NM 020393 PGLYRP4 18,721 0.78 4.57 0.27 5.84 0.52
219170 at NM 024333 FSD1 19,171 0.91 5.35 0.24 5.9 0.36
221113 s at NM 016087 WNT16 15,738 1.03 6.15 0.17 5.95 0.28
221431 s at NM 030959 OR12D3 948 0.68 4.08 0.23 6.03 0.31
207936 x at NM 006604 RFPL3 6277 0.64 3.96 0.36 6.16 0.47
204303 s at NM 014772 KIAA0427 324,158 0.99 6.01 0.31 6.09 0.17
210272 at M29873 CYP2B7P1 26,394 0.74 4.69 0.23 6.35 0.38
207984 s at NM 005374 MPP2 32,387 0.64 4.07 0.25 6.36 0.26
208227 x at NM 021721 ADAM22 262,753 0.69 4.55 0.31 6.56 0.35
213847 at NM 006262 PRPH 4997 0.84 5.63 0.33 6.71 0.42
215544 s at AL121891 UBOX5 14,320 0.85 5.83 0.23 6.85 0.31
336 at D38081 TBXA2R 12,155 0.74 5.03 0.24 6.84 0.28
209402 s at AF047338 SLC12A4 24,296 1 6.97 0.26 7 0.25
221629 x at AF151022 LOC51236 2948 0.83 6.04 0.58 7.29 0.5
219071 x at NM 016458 C8orf30A 2948 1.03 8.12 0.71 7.92 0.52
56829 at H61826 NIBP 726,091 0.82 6.83 0.27 8.29 0.3
205835 s at AW975818 YTHDC2 81,572 0.9 4.11 0.17 4.59 0.19
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Table 3: Continued.
Group Colon carcinoma Colon carcinoma
Samples; n 31 24
Stage UICC III III
Amplified yes no
213254 at N64803 TNRC6B 290,992 0.93 6.15 0.23 6.65 0.38
34764 at D21851 LARS2 160,261 1.01 7.13 0.63 7.04 0.51
209711 at N80922 SLC35D1 50,402 1.32 10.2 0.52 7.73 0.45
203073 at NM 007357 COG2 51,491 1 8.11 0.51 8.07 0.3
209174 s at BC000978 FLJ20259 64,363 1.07 8.71 0.32 8.17 0.25
221884 at BE466525 EVI1 64,236 1.25 10.56 0.66 8.46 0.46
218160 at NM 014222 NDUFA8 15,762 1.22 11.3 0.38 9.24 0.47
201386 s at AF279891 DHX15 57,098 1.08 10.44 0.66 9.64 0.52
202753 at NM 014814 PSMD6 13,281 1.14 11.46 0.44 10.03 0.46
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Figure 4: Comparison of mean signals (HG-U 133A, Aﬀymetrix)
between RNA samples of 31 colon carcinomas amplified and
24 RNA samples of colon carcinomas not amplified prior to
microarray hybridization.
genes demonstrate an amplification bias between native and
amplified RNA. The correlation of microarray signal NA
versus PA was between 86–91%. This amplification bias
could be validated in a cohort of 55 RNA samples either
amplified or not amplified from colon carcinoma samples
(stage UICC III). The correlation of 22.115 probe set signals
did reached only 80% and the comparison of 50 genes
involved in lymphatic metastasis varied substantially. If the
same labelled cRNA is hybridized twice to microarrays the
correlation of signals is 99%. When two cRNA samples
are generated from the same mRNA and hybridized to
microarrays, the correlation of signals is about 99% as well.
Signal correlations of 97% were reached with two separate
RNA isolations and microarray hybridizations of one and
the same tumour probe (data not published). Behind these
findings, the identified diﬀerences between amplified and
non amplified RNA are relevant. Analysing the reasons for
these findings we detected that sequences with a length of
bp 1000–19000 are mainly aﬀected by diﬀerential signal
intensity. This may be explained due to the more frequent
amplification of shorter transcripts which may be dependent
on the amount of amplification rounds. A connection of
sequences located on specific chromosomes could not be
identified. These findings are supported by previous studies
which identified a correlation between amplification rounds
and comparability between native and amplified RNA [18].
The detected alterations during RNA amplification are
important, because several genes of interest involved in
carcinogenesis (e.g., APC, VEGF) and tumour progression
(e.g., CDC2, MMPs) were aﬀected. When amplified and
non amplified RNA are compared in the same microarray
study false positive results might occur. Therefore, amplified
and non amplified RNA should not be compared during
microarray investigations. These findings have already been
suspected previously, but have not been demonstrated in
detail so far [18, 19].
5. Conclusion
Amplification of RNA by the T7-IVT is an elegant method
to generate RNA in good quality and suﬃcient yield for
microarray hybridization from as less as 200 ng of starting
RNA. Nevertheless during amplification alterations occur
which lead to an amplification bias compared to non
amplified RNA. For this reason the microarray results of
amplified and non amplified RNA samples should not be
compared within the same study.
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